1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Colorectal cancer

Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency

Technology appraisal guidance [TA709] Published: 23 June 2021

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

History

A list of downloadable documents created during development.

Expected publication

  • Equality Impact Assessment (Guidance development) PDF 152 KB 23 June 2021  

Declaration of interests

  • Register of interests MSWord 41 KB 26 August 2021  

Final draft guidance

  • Final draft guidance  
  • Committee papers PDF 5.09 MB 14 May 2021  
  • Final appraisal document PDF 313 KB 14 May 2021  
  • Public committee slides PDF 2.4 MB 14 May 2021  

Invitation to participate

  • Final scope PDF 196 KB 28 July 2020  
  • Final stakeholder list PDF 194 KB 28 July 2020  
  • Equality Impact Assessment (Guidance development) PDF 121 KB 28 July 2020  
  • NICE's response to comments on the draft scope and provisional stakeholder list PDF 270 KB 28 July 2020  

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1

  • Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 1  
  • Draft scope post referral PDF 210 KB 09 June 2020  
  • Draft matrix post referral PDF 194 KB 09 June 2020  

Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

  • Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators  
  • Draft scope post referral PDF 341 KB 22 November 2018  
  • Draft matrix post referral PDF 263 KB 22 November 2018